Advanced Glycation End Products Drive Blood-Brain Barrier Lipid Dysregulation Via RAGE-Abca1 Signaling To Promote Neurovascular Dysfunction In Alzheimer’S Disease
Our brains are protected by a highly selective “blood-brain barrier” (BBB), a crucial shield that controls what enters and exits the brain, maintaining its delicate environment. In conditions like Alzheimer’s disease, this barrier can become dysfunctional, contributing to the progression of the illness. Recent research sheds light on a key player in this dysfunction: Advanced Glycation End Products, or AGEs. These are harmful compounds that accumulate in our bodies as we age and when we experience metabolic stress, such as from high blood sugar.
This study reveals that AGEs build up in the tiny blood vessels of the brain, leading to the formation of lipid droplets—small pockets of fat—within the cells lining these vessels. This process is driven by a specific receptor called RAGE, which, when activated by AGEs, disrupts the normal pathways that remove cholesterol from these cells.
Researchers observed higher levels of AGEs and RAGE, along with reduced levels of a protein called ABCA1 (which is important for removing cholesterol), in the brains of individuals with Alzheimer’s and in aged animal models. Furthermore, exposure to AGEs was shown to make the blood-brain barrier leaky and hinder the removal of amyloid-beta, a protein known to accumulate in Alzheimer’s disease.
Crucially, the study found that boosting the activity of ABCA1 could reverse the AGE-induced fat accumulation and reduce RAGE levels, suggesting a promising new avenue for therapeutic intervention. These findings establish a clear link between metabolic stress and the neurovascular dysfunction seen in Alzheimer’s disease, offering a deeper understanding of the disease’s mechanisms and potential targets for treatment.
Source: link to paper